These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38539256)

  • 1. Concurrent KRAS p.G12C mutation and ANK3::RET fusion in a patient with metastatic colorectal cancer: a case report.
    Bedau T; Heydt C; Siebolts U; Zander T; Kraemer M; Loeser H; Buettner R; Quaas A
    Diagn Pathol; 2024 Mar; 19(1):55. PubMed ID: 38539256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
    Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
    BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting KRAS
    Ciardiello D; Maiorano BA; Martinelli E
    ESMO Open; 2023 Feb; 8(1):100745. PubMed ID: 36549128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of RET fusions in advanced colorectal cancer.
    Le Rolle AF; Klempner SJ; Garrett CR; Seery T; Sanford EM; Balasubramanian S; Ross JS; Stephens PJ; Miller VA; Ali SM; Chiu VK
    Oncotarget; 2015 Oct; 6(30):28929-37. PubMed ID: 26078337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population.
    Schirripa M; Nappo F; Cremolini C; Salvatore L; Rossini D; Bensi M; Businello G; Pietrantonio F; Randon G; Fucà G; Boccaccino A; Bergamo F; Lonardi S; Dei Tos AP; Fassan M; Loupakis F
    Clin Colorectal Cancer; 2020 Sep; 19(3):219-225. PubMed ID: 32605718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting
    Ros J; Vaghi C; Baraibar I; Saoudi González N; Rodríguez-Castells M; García A; Alcaraz A; Salva F; Tabernero J; Elez E
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.
    Chida K; Kotani D; Masuishi T; Kawakami T; Kawamoto Y; Kato K; Fushiki K; Sawada K; Kumanishi R; Shirasu H; Matsubara Y; Yuki S; Komatsu Y; Yamazaki K; Yoshino T
    Oncologist; 2021 Oct; 26(10):845-853. PubMed ID: 34232546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer.
    Fakih M; Tu H; Hsu H; Aggarwal S; Chan E; Rehn M; Chia V; Kopetz S
    Oncologist; 2022 Aug; 27(8):663-674. PubMed ID: 35472176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Clinical and Molecular Characterization of
    Henry JT; Coker O; Chowdhury S; Shen JP; Morris VK; Dasari A; Raghav K; Nusrat M; Kee B; Parseghian C; Pant S; Jeyakumar N; Zhu L; Nishioka Y; Fogelman D; Wolff RA; Hong D; Overman MJ; Vauthey J; Kopetz S; Johnson B
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors.
    Matsubara H; Miyoshi H; Kakizaki F; Morimoto T; Kawada K; Yamamoto T; Obama K; Sakai Y; Taketo MM
    Mol Cancer Ther; 2023 Apr; 22(4):529-538. PubMed ID: 36780229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer.
    Zhu G; Pei L; Xia H; Tang Q; Bi F
    Mol Cancer; 2021 Nov; 20(1):143. PubMed ID: 34742312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.
    Arbour KC; Rizvi H; Plodkowski AJ; Hellmann MD; Knezevic A; Heller G; Yu HA; Ladanyi M; Kris MG; Arcila ME; Rudin CM; Lito P; Riely GJ
    Clin Cancer Res; 2021 Apr; 27(8):2209-2215. PubMed ID: 33558425
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Jones GD; Caso R; Tan KS; Mastrogiacomo B; Sanchez-Vega F; Liu Y; Connolly JG; Murciano-Goroff YR; Bott MJ; Adusumilli PS; Molena D; Rocco G; Rusch VW; Sihag S; Misale S; Yaeger R; Drilon A; Arbour KC; Riely GJ; Rosen N; Lito P; Zhang H; Lyden DC; Rudin CM; Jones DR; Li BT; Isbell JM
    Clin Cancer Res; 2021 May; 27(9):2604-2612. PubMed ID: 33593884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
    Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
    Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Characterization of Targetable Mutations (BRAF V600E and KRAS G12C) in Advanced Colorectal Cancer-A Nation-Wide Study.
    Potocki PM; Wójcik P; Chmura Ł; Goc B; Fedewicz M; Bielańska Z; Swadźba J; Konopka K; Kwinta Ł; Wysocki PJ
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.
    Veluswamy R; Mack PC; Houldsworth J; Elkhouly E; Hirsch FR
    J Mol Diagn; 2021 May; 23(5):507-520. PubMed ID: 33618059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review.
    Strickler JH; Yoshino T; Stevinson K; Eichinger CS; Giannopoulou C; Rehn M; Modest DP
    Oncologist; 2023 Nov; 28(11):e981-e994. PubMed ID: 37432264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in-Humans PET Imaging of
    Li X; Ye J; Wang J; Quan Z; Li G; Ma W; Zhang M; Yang W; Wang J; Ma T; Kang F; Wang J
    J Nucl Med; 2023 Dec; 64(12):1880-1888. PubMed ID: 37827842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS
    Li S; Liu S; Deng J; Akbay EA; Hai J; Ambrogio C; Zhang L; Zhou F; Jenkins RW; Adeegbe DO; Gao P; Wang X; Paweletz CP; Herter-Sprie GS; Chen T; Gutiérrez-Quiceno L; Zhang Y; Merlino AA; Quinn MM; Zeng Y; Yu X; Liu Y; Fan L; Aguirre AJ; Barbie DA; Yi X; Wong KK
    Clin Cancer Res; 2018 Oct; 24(19):4854-4864. PubMed ID: 29945997
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.